Elvitegravir

Elvitegravir
Clinical data
Trade names	Vitekta; Stribild (fixed-dose combination)
Other names	GS-9137
License data	EU EMA: by INN;
Routes of; administration	By mouth
ATC code	J05AJ02 (WHO) ;
Pharmacokinetic data
Protein binding	98%
Metabolism	liver, via CYP3A
Elimination half-life	12.9 (8.7–13.7) hours
Excretion	liver 93%, renal 7%
Identifiers
	IUPAC name 6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid;
CAS Number	697761-98-1 ;
PubChem CID	5277135;
DrugBank	DB09101 ;
ChemSpider	4441060 ;
UNII	4GDQ854U53;
KEGG	D06677 ;
ChEBI	CHEBI:72289 ;
ChEMBL	ChEMBL204656 ;
NIAID ChemDB	241767;
CompTox Dashboard (EPA)	DTXSID101021650 ;
Chemical and physical data
Formula	C23H23ClFNO5
Molar mass	447.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cccc(c1F)Cc3c(OC)cc2c(C(=O)\C(=C/N2[C@H](CO)C(C)C)C(=O)O)c3;
	InChI InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1 ; Key:JUZYLCPPVHEVSV-LJQANCHMSA-N ;
	(what is this?) (verify)

Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on 27 August 2012, for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On 24 September 2014, the FDA approved Elvitegravir as a single pill formulation under the trade name Vitekta. On 5 November 2015, the FDA approved the drug for use in patients affected with HIV-1 as a part of a second fixed dose combination pill known as Genvoya.

According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.